A Phase 3 interventional study of Denosumab and Alternative osteoporosis medications in Osteogenesis Imperfecta (OI), sponsored by Amgen. Terminated at 22 sites in 12 countries. Per ClinicalTrials.gov, last updated 2022-12-20.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Osteogenesis Imperfecta with a site in United Kingdom — 1 open to participants now, 3 under way, 2 of them phase 3. Osteogenesis Imperfecta · United Kingdom.
Among the 10 studies in Osteogenesis Imperfecta with a site in United Kingdom, this one is the 8th largest by enrollment, is the only one that started in 2018, is one of 4 in phase 3, and was the 6th registered.
84 studies on the registry are indexed under Osteogenesis Imperfecta; 20 are open to participants now.
Browse Osteogenesis Imperfecta studies →1 of the 10 studies in Osteogenesis Imperfecta with a site in United Kingdom is open now. Recruiting first, the newest first:
Angitia Incorporated Limited · Sites in United Kingdom, United States, Argentina and 5 more countries
Ages 18–75
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 14 Osteogenesis Imperfecta studies recruiting now, 4 (29%) set no upper age limit and 8 (57%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 5 · Phase 4 1
First in 2004; this study’s year is marked. 1 started in 2018.
This study's enrollment of 75 is above the median of 28 across 60 interventional studies indexed under Osteogenesis Imperfecta.
Median enrollment 112 across the 10 interventional studies. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 7 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 5 studies filed under Osteogenesis Imperfecta — fewer than ten, so there is no comparison to draw.
2 of the studies in Osteogenesis Imperfecta with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05972551Phase 3AmgenStudy to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta | 2027-05-04 |
| NCT07062588Angitia Incorporated LimitedOsteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN) | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Osteogenesis Imperfecta with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate long-term safety of denosumab in children/young adults with pediatric osteogenesis imperfecta (OI) who completed the prior study 20130173 (NCT02352753).
All participants who completed the prior denosumab study 20130173 (NCT02352753) were offered participation in this study (20170534). Participants could continue to receive denosumab once every 3 months (Q3M) or could receive denosumab once every 6 months (Q6M) or off-treatment observation only at the investigator's discretion. The study design allowed subjects to discontinue denosumab, resume denosumab, initiate alternative osteoporosis medication, discontinue alternative osteoporosis medication, or receive no treatment (observation only) at any time. Therefore results of this study were analyzed according to both baseline treatment and subsequent treatment trajectories.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject is currently/was enrolled in Study 20130173 and
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received non-denosumab alternative therapy during the study or who were not receiving any medication at baseline. Alternative osteoporosis medication(s) were determined at the investigator's discretion and per standard of care and local guidelines.
Drug: Alternative osteoporosis medications
Participants who received at least 1 dose of 1 mg/kg denosumab administered once every 6 months (Q6M) by subcutaneous injection, but no Q3M denosumab during this study.
Drug: Denosumab
Participants who received at least one dose of 1 mg/kg denosumab administered once every 3 months (Q3M) by subcutaneous injection during this study.
Drug: Denosumab
Solution for injection
Also known as: Prolia
Alternative osteoporosis medication/s at the discretion of the investigator.
Number of Participants With Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest
A Serious Adverse Event is defined as any untoward medical occurrence that met at least 1 of the following serious criteria: * Resulted in death (fatal) * Immediately life-threatening * Required in-patient hospitalization or prolongation of existing hospitalization * Resulted in persistent or significant disability/incapacity * Was a congenital anomaly/birth defect * Other medically important serious event that may have jeopardized the participant or require medical or surgical intervention to prevent 1 of the outcomes listed above. Adverse events of special interest included hypocalcemia, hypersensitivity, bacterial cellulitis, osteonecrosis of the jaw (ONJ), hypercalcemia, and typical osteogenesis imperfecta (OI) femur fractures.
Time frame: From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months.
Number of Participants With Anti-denosumab Antibodies
Blood samples were collected (from denosumab treated participants only) for the measurement of anti-denosumab binding antibodies. Samples positive for anti-denosumab binding antibodies were further tested for neutralizing antibodies.
Time frame: From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months
Number of Participants With Clinical Laboratory Toxicities Grade ≥ 3
Laboratory abnormalities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. The grades refer to the severity of the finding: Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe or medically significant; Grade 4 = Life-threatening consequences, urgent intervention indicated.
Time frame: From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months
Number of Participants With Clinically Significant Vital Sign Findings
Vital sign measurements included systolic and diastolic blood pressure, heart rate, respiratory rate, and temperature. The investigator assessed vital sign results and determined whether any abnormal changes represented a clinically significant change from the participant's baseline values.
Time frame: From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months
Number of Participants With Metaphyseal Index Z-score Above Age-appropriate Normal Range
Anteroposterior radiographs of both knees (unless prohibited by the presence of hardware such as implants) were used to calculate the metaphyseal index Z-score of each knee in participants with open growth plates; the knee selected for assessment during the study was the knee with the higher Z-score at baseline. The metaphyseal index (MI) was calculated by the central imaging vendor as the ratio of femoral width over distal femoral growth plate width, and the Z-score for each participant, relative to the participant's age as: MI Z-score = (participant value - mean)/SD, where mean and standard deviation (SD) are the corresponding values based on a reference population for the participant's age group at the time of the assessment. Metaphyseal index Z-score above age-appropriate normal range is defined as a MI Z-score \> 2.
Time frame: Baseline, month 12 and month 24
Number of Participants With Abnormal Molar Eruption of the First or Second Molar Based on Radiological Findings
Participants underwent a visual inspection under natural light for the presence of the first and second molars. Participants were referred to a dentist to perform radiographic assessment of the unerupted molar(s) if: * A participant was age 7 to 12 years and appeared to have an unerupted upper or lower first molar (ie, not all 4 first molars were visible/detectable). * A participant was age 13 years or older and appeared to have an unerupted upper or lower (first or) second molar (ie, not all 4 first molars and all 4 second molars were visible/detectable). Abnormal molar eruptions includes the number of participants 7 to 12 years of age with 1st unerupted or partially erupted molars and participants 13 years of age or older with 2nd unerupted or partially erupted molars.
Time frame: Baseline, month 12, and month 24
Percent Change From Baseline in Mandibular Shaping Parameters
Lateral cephalogram was performed to enable assessment of mandibular shaping. The lateral cephalogram is a profile X-ray of the skull and soft tissues and is used to assess the relation of the teeth in the jaws, the relation of the jaws to the skull, and the relation of the soft tissues to the teeth and jaws. The following anatomical angles and dimensions were measured to evaluate the correct proportions of the mandible and its position relative to the skull/maxilla: Gonial angle; Sella-Nasion-A Point Angle (SNA angle); Sella-Nasion-B Point Angle (SNB angle); and A Point - Nasion-B Point Angle (ANB Angle).
Time frame: Baseline and month 12 and month 24
Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-score
Bone densitometry assessments of the lumbar spine were performed using dual X-ray absorptiometry (DXA). The Z-score indicates the number of standard deviations away from the mean of an average person of the same age, sex, race, and weight. A Z-score of 0 is equal to the mean of the matched population, negative Z-scores indicate a BMD lower than the mean of the matched population, and positive Z-scores indicate a higher BMD than that of the matched population. A positive change from baseline indicates an improvement in lumbar spine BMD.
Time frame: Baseline and months 6, 12, and 24
Change From Baseline in Total Hip BMD Z-score
Bone densitometry assessments of the hip were performed using dual X-ray absorptiometry (DXA). The Z-score indicates the number of standard deviations away from the mean of an average person of the same age, sex, race, and weight. A Z-score of 0 is equal to the mean of the matched population, negative Z-scores indicate a BMD lower than the mean of the matched population, and positive Z-scores indicate a higher BMD than that of the matched population. A positive change from baseline indicates an improvement in total hip BMD.
Time frame: Baseline, months 6, 12, and 24
Change From Baseline in Femoral Neck BMD Z-score
Bone densitometry assessments of the femoral neck were performed using dual X-ray absorptiometry (DXA). The Z-score indicates the number of standard deviations away from the mean of an average person of the same age, sex, race, and weight. A Z-score of 0 is equal to the mean of the matched population, negative Z-scores indicate a BMD lower than the mean of the matched population, and positive Z-scores indicate a higher BMD than that of the matched population. A positive change from baseline indicates an improvement in femoral neck BMD.
Time frame: Baseline and months 6, 12, and 24
This study was conducted at 22 centers in North America, Europe, and Australia from July 2018 to March 2022. The study was an open-label extension of study 20130173 (NCT02352753). Participants who completed the end of study visit or who withdrew consent or assent to transition to every 3 months (Q3M) dosing regimen in Study 20130173 were offered participation in this study.
| Milestone | Alternative Medications / Observational | Denosumab 1 mg/kg Q6M | Denosumab 1 mg/kg Q3M |
|---|---|---|---|
| Started | 21 | 27 | 27 |
| Completed | 5 | 8 | 1 |
| Not completed | 16 | 19 | 26 |
| Withdrew: Withdrawal by subject | 1 | 7 | 6 |
| Withdrew: Sponsor decision | 15 | 12 | 19 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
A Serious Adverse Event is defined as any untoward medical occurrence that met at least 1 of the following serious criteria: * Resulted in death (fatal) * Immediately life-threatening * Required in-patient hospitalization or prolongation of existing hospitalization * Resulted in persistent or significant disability/incapacity * Was a congenital anomaly/birth defect * Other medically important serious event that may have jeopardized the participant or require medical or surgical intervention to prevent 1 of the outcomes listed above. Adverse events of special interest included hypocalcemia, hypersensitivity, bacterial cellulitis, osteonecrosis of the jaw (ONJ), hypercalcemia, and typical osteogenesis imperfecta (OI) femur fractures.
| Participants | Alternative Medications / Observational | Denosumab 1 mg/kg Q6M | Denosumab 1 mg/kg Q3M |
|---|---|---|---|
| Any adverse event | 18 | 22 | 19 |
| Serious adverse events | 6 | 5 | 6 |
| Adverse events of special interest | 5 | 5 | 9 |
| Hypocalcemia | 0 | 0 | 1 |
| Hypercalcemia | 3 | 4 | 9 |
| Hypersensitivity | 0 | 0 | 0 |
| Bacterial cellulitis (skin infection) | 0 | 0 | 0 |
| Typical osteogenesis imperfecta femur fractures | 2 | 1 | 2 |
| Positively adjudicated osteonecrosis of the jaw | 0 | 0 | 0 |
Blood samples were collected (from denosumab treated participants only) for the measurement of anti-denosumab binding antibodies. Samples positive for anti-denosumab binding antibodies were further tested for neutralizing antibodies.
| Participants | Denosumab 1 mg/kg Q6M | Denosumab 1 mg/kg Q3M |
|---|---|---|
| Anti-denosumab binding antibodies | 0 | 0 |
| Anti-denosumab neutralizing antibodies | 0 | 0 |
Laboratory abnormalities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. The grades refer to the severity of the finding: Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe or medically significant; Grade 4 = Life-threatening consequences, urgent intervention indicated.
| Participants | Alternative Medications / Observational | Denosumab 1 mg/kg Q6M | Denosumab 1 mg/kg Q3M |
|---|---|---|---|
| Number of Participants With Clinical Laboratory Toxicities Grade ≥ 3 | 0 | 0 | 0 |
Vital sign measurements included systolic and diastolic blood pressure, heart rate, respiratory rate, and temperature. The investigator assessed vital sign results and determined whether any abnormal changes represented a clinically significant change from the participant's baseline values.
| Participants | Alternative Medications / Observational | Denosumab 1 mg/kg Q6M | Denosumab 1 mg/kg Q3M |
|---|---|---|---|
| Number of Participants With Clinically Significant Vital Sign Findings | 0 | 0 | 0 |
Anteroposterior radiographs of both knees (unless prohibited by the presence of hardware such as implants) were used to calculate the metaphyseal index Z-score of each knee in participants with open growth plates; the knee selected for assessment during the study was the knee with the higher Z-score at baseline. The metaphyseal index (MI) was calculated by the central imaging vendor as the ratio of femoral width over distal femoral growth plate width, and the Z-score for each participant, relative to the participant's age as: MI Z-score = (participant value - mean)/SD, where mean and standard deviation (SD) are the corresponding values based on a reference population for the participant's age group at the time of the assessment. Metaphyseal index Z-score above age-appropriate normal range is defined as a MI Z-score \> 2.
| Participants | Alternative Medications / Observational | Denosumab 1 mg/kg Q6M | Denosumab 1 mg/kg Q3M |
|---|---|---|---|
| Baseline | 2 | 1 | 0 |
| Month 12 | 2 | 1 | 0 |
| Month 24 | 1 | 0 | — |
Participants underwent a visual inspection under natural light for the presence of the first and second molars. Participants were referred to a dentist to perform radiographic assessment of the unerupted molar(s) if: * A participant was age 7 to 12 years and appeared to have an unerupted upper or lower first molar (ie, not all 4 first molars were visible/detectable). * A participant was age 13 years or older and appeared to have an unerupted upper or lower (first or) second molar (ie, not all 4 first molars and all 4 second molars were visible/detectable). Abnormal molar eruptions includes the number of participants 7 to 12 years of age with 1st unerupted or partially erupted molars and participants 13 years of age or older with 2nd unerupted or partially erupted molars.
| Participants | Alternative Medications / Observational | Denosumab 1 mg/kg Q6M | Denosumab 1 mg/kg Q3M |
|---|---|---|---|
| Baseline | 2 | 3 | 1 |
| Month 12 | 0 | 0 | 2 |
| Month 24 | 1 | 1 | 0 |
Lateral cephalogram was performed to enable assessment of mandibular shaping. The lateral cephalogram is a profile X-ray of the skull and soft tissues and is used to assess the relation of the teeth in the jaws, the relation of the jaws to the skull, and the relation of the soft tissues to the teeth and jaws. The following anatomical angles and dimensions were measured to evaluate the correct proportions of the mandible and its position relative to the skull/maxilla: Gonial angle; Sella-Nasion-A Point Angle (SNA angle); Sella-Nasion-B Point Angle (SNB angle); and A Point - Nasion-B Point Angle (ANB Angle).
| percent change | Alternative Medications / Observational | Denosumab 1 mg/kg Q6M | Denosumab 1 mg/kg Q3M |
|---|---|---|---|
| Gonial angle: month 12 | 0.5 ± 2.4 | -1.4 ± 1.7 | -1.0 |
| Gonial angle: month 24 | -2.1 ± 3.1 | -1.4 ± 2.2 | — |
| SNA angle: month 12 | 1.38 ± 2.09 | 0.37 ± 2.41 | 0.20 |
| SNA angle: month 24 | -0.07 ± 0.73 | -1.70 ± 1.79 | — |
| SNB angle: month 12 | 0.98 ± 1.56 | 1.75 ± 2.36 | 0.70 |
| SNB angle: month 24 | 1.28 | -1.60 ± 3.18 | — |
| ANB angle: month 12 | -81.06 ± 199.39 | 127.48 ± 312.99 | -16.26 |
| ANB angle: month 24 | -79.69 | 15.65 ± 84.75 | — |
Bone densitometry assessments of the lumbar spine were performed using dual X-ray absorptiometry (DXA). The Z-score indicates the number of standard deviations away from the mean of an average person of the same age, sex, race, and weight. A Z-score of 0 is equal to the mean of the matched population, negative Z-scores indicate a BMD lower than the mean of the matched population, and positive Z-scores indicate a higher BMD than that of the matched population. A positive change from baseline indicates an improvement in lumbar spine BMD.
| Z-score | Any Treatment |
|---|---|
| Month 6 | -0.11 ± 0.60 |
| Month 12 | -0.01 ± 0.48 |
| Month 24 | 0.21 ± 0.49 |
Bone densitometry assessments of the hip were performed using dual X-ray absorptiometry (DXA). The Z-score indicates the number of standard deviations away from the mean of an average person of the same age, sex, race, and weight. A Z-score of 0 is equal to the mean of the matched population, negative Z-scores indicate a BMD lower than the mean of the matched population, and positive Z-scores indicate a higher BMD than that of the matched population. A positive change from baseline indicates an improvement in total hip BMD.
| Z-score | Any Treatment |
|---|---|
| Month 6 | -0.07 ± 0.40 |
| Month 12 | 0.24 ± 0.42 |
| Month 24 | 0.50 ± 0.54 |
Bone densitometry assessments of the femoral neck were performed using dual X-ray absorptiometry (DXA). The Z-score indicates the number of standard deviations away from the mean of an average person of the same age, sex, race, and weight. A Z-score of 0 is equal to the mean of the matched population, negative Z-scores indicate a BMD lower than the mean of the matched population, and positive Z-scores indicate a higher BMD than that of the matched population. A positive change from baseline indicates an improvement in femoral neck BMD.
| Z-score | Any Treatment |
|---|---|
| Month 6 | 0.08 ± 0.44 |
| Month 12 | 0.24 ± 0.39 |
| Month 24 | 0.45 ± 0.58 |
Collected over From enrollment to end of study, including 24 weeks after last dose of denosumab for participants who received denosumab; the maximum time on study was 24 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alternative Medications / Observational | 0/21 (0%) | 6/21 (28.6%) | 15/21 (71.4%) |
| Denosumab 1 mg/kg Q6M | 0/27 (0%) | 5/27 (18.5%) | 21/27 (77.8%) |
| Denosumab 1 mg/kg Q3M | 0/27 (0%) | 6/27 (22.2%) | 13/27 (48.1%) |
| Event | Alternative Medications / Observational | Denosumab 1 mg/kg Q6M | Denosumab 1 mg/kg Q3M |
|---|---|---|---|
| HypercalcaemiaMetabolism and nutrition disorders | 0/21 | 0/27 | 5/27 |
| Femur fractureInjury, poisoning and procedural complications | 2/21 | 1/27 | 1/27 |
| Forearm fractureInjury, poisoning and procedural complications | 2/21 | 1/27 | 0/27 |
| Fibula fractureInjury, poisoning and procedural complications | 0/21 | 2/27 | 0/27 |
| Tibia fractureInjury, poisoning and procedural complications | 0/21 | 2/27 | 0/27 |
| AppendicitisInfections and infestations | 1/21 | 0/27 | 0/27 |
| Lower limb fractureInjury, poisoning and procedural complications | 1/21 | 0/27 | 0/27 |
| Ulna fractureInjury, poisoning and procedural complications | 1/21 | 1/27 | 0/27 |
| NephrolithiasisRenal and urinary disorders | 1/21 | 1/27 | 0/27 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/21 | 0/27 | 0/27 |
| Event | Alternative Medications / Observational | Denosumab 1 mg/kg Q6M | Denosumab 1 mg/kg Q3M |
|---|---|---|---|
| HypercalciuriaRenal and urinary disorders | 11/21 | 15/27 | 1/27 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/21 | 7/27 | 4/27 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/21 | 7/27 | 0/27 |
| HypercalcaemiaMetabolism and nutrition disorders | 3/21 | 4/27 | 5/27 |
| Back painMusculoskeletal and connective tissue disorders | 3/21 | 4/27 | 3/27 |
| HeadacheNervous system disorders | 3/21 | 1/27 | 2/27 |
| Abdominal pain upperGastrointestinal disorders | 2/21 | 0/27 | 0/27 |
| PyrexiaGeneral disorders | 0/21 | 0/27 | 2/27 |
| COVID-19Infections and infestations | 1/21 | 1/27 | 2/27 |
| Ankle fractureInjury, poisoning and procedural complications | 0/21 | 0/27 | 2/27 |
| Age, Continuous(years) | Alternative Medications / Observational | Denosumab 1 mg/kg Q6M | Denosumab 1 mg/kg Q3M | Total |
|---|---|---|---|---|
| Mean | 12.5 ± 3.5 | 13.2 ± 2.5 | 14.3 ± 4.8 | 13.4 ± 3.8 |
| Sex: Female, Male(Participants) | Alternative Medications / Observational | Denosumab 1 mg/kg Q6M | Denosumab 1 mg/kg Q3M | Total |
|---|---|---|---|---|
| Female | 8 | 9 | 13 | 30 |
| Male | 13 | 18 | 14 | 45 |
| Ethnicity (NIH/OMB)(Participants) | Alternative Medications / Observational | Denosumab 1 mg/kg Q6M | Denosumab 1 mg/kg Q3M | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 3 | 4 |
| Not Hispanic or Latino | 20 | 27 | 24 | 71 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Alternative Medications / Observational | Denosumab 1 mg/kg Q6M | Denosumab 1 mg/kg Q3M | Total |
|---|---|---|---|---|
| Asian | 0 | 0 | 1 | 1 |
| Black or African American | 1 | 1 | 0 | 2 |
| White | 20 | 25 | 23 | 68 |
| Other | 0 | 1 | 1 | 2 |
| Multiple | 0 | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Jul 2018 to primary completion in Mar 2022, 44 months.
Results were first posted in Dec 2022, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab